Stocks of Seres Therapeutics Inc (NASDAQ:MCRB) traded higher last session on Wall Street, up 7.72% to $1.04.
According to the data, Seres Therapeutics Inc (NASDAQ:MCRB) has 7 analysts covering its stock. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $15.00 and a low of $1.25, we find $10.00. Given the previous closing price of $0.97, this indicates a potential upside of 930.93 percent. MCRB stock price is now -41.46% away from the 50-day moving average and -75.14% away from the 200-day moving average. The market capitalization of the company currently stands at $135.08M.
A total of 1 analysts have issued a hold rating and 5 have given it a buy rating. Brokers who have rated the stock have averaged $9.25 as their price target over the next twelve months.
In other news, Shaff Eric D., CEO and President sold 8,552 shares of the company’s stock on Oct 30. The stock was sold for $11,545 at an average price of $1.35. Upon completion of the transaction, the CEO and President now directly owns 115,620 shares in the company, valued at $0.12 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Oct 30, von Moltke Lisa sold 4,232 shares of the business’s stock. A total of $5,713 was realized by selling the stock at an average price of $1.35. This leaves the insider owning 9,513 shares of the company worth $9893.52. Insiders disposed of 41,807 shares of company stock worth roughly $43479.28 over the past 1 year. A total of 24.81% of the company’s stock is owned by insiders.
Tuesday’s opening bell rang with an opening price of $1.0700 for Seres Therapeutics Inc (NASDAQ: MCRB). During the past 12 months, Seres Therapeutics Inc has had a low of $0.91 and a high of $7.30. The fifty day moving average price for MCRB is $1.7850 and a two-hundred day moving average price translates $4.2043 for the stock.
The latest earnings results from Seres Therapeutics Inc (NASDAQ: MCRB) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at -$0.37, beating analysts’ expectations of -$0.5 by 0.13. This compares to -$0.49 EPS in the same period last year. The net profit margin was -111.03% and return on equity was -538.57% for MCRB. The company reported revenue of $0.31 million for the quarter, compared to $3.44 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -91.0 percent. For the current quarter, analysts expect MCRB to generate $350k in revenue.
Seres Therapeutics Inc(MCRB) Company Profile
Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company’s lead product candidate is SER-109, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes SER-109 product candidate, which is developed for the treatment of CDI and recurrent CDI; collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn’s disease; research collaboration and option agreement with AstraZeneca Inc. for research and develop of microbiome in certain cancers and cancer immunotherapies, including research program for SER-401 targeting various cancers. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
